Beam Therapeutics Inc. Common Stock (BEAM) is a publicly traded Healthcare sector company. As of November 16, 2026, BEAM trades at $23.08 with a market cap of $2.36B and a P/E ratio of -35.79. BEAM moved +1.10% today. Year to date, BEAM is -15.88%; over the trailing twelve months it is +5.40%. Its 52-week range spans $13.53 to $38.26. Analyst consensus is strong buy with an average price target of $49.31. Rallies surfaces BEAM's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Beam’s risto-cel meets BEACON endpoints; BLA planned as early as year-end 2026: Beam Therapeutics said its BEACON Phase 1/2 trial of risto-cel met its primary efficacy endpoint and all primary safety and secondary endpoints. The company plans to submit a U.S. BLA as early as year-end 2026, with detailed pivotal results planned for a medical meeting in 2027.
| Metric | Value |
|---|---|
| Price | $23.08 |
| Market Cap | $2.36B |
| P/E Ratio | -35.79 |
| EPS | $-0.68 |
| Dividend Yield | 0.23% |
| 52-Week High | $38.26 |
| 52-Week Low | $13.53 |
| Volume | 2.83K |
| Avg Volume | 0 |
| Revenue (TTM) | $156.03M |
| Net Income | $-85.43M |
| Gross Margin | 0.00% |
14 analysts cover BEAM: 0 strong buy, 12 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $49.31.